Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Medical Oncology
Would an STK11 mutation influence your choice of single vs combination immunotherapy in a patient with MSI-H metastatic CRC?
Patient with initially stage IIIC right sided colon cancer s/p resection found to have metastatic disease prior to starting adjuvant therapy. MSI-H and STK11 mutated.
Answer from: Medical Oncologist at Academic Institution
The presence of an STK11 mutation would not affect my decision to offer immunotherapy for an MSI-high (dMMR) colorectal cancer patient. There is mixed literature about if this might portend a better response to IO treatment (Kwon et al., PMID 32284250.) One should note that with a KRAS mutation in l...
Sign in or Register to read more